Both in Biotechnology
ADMA Biologics vs Recursion Pharmaceuticals
Over the past year ADMA returned −32.2% and RXRX returned −17.9%; their daily moves had a correlation of 0.24.
ADMA −32.2% RXRX −17.9%Growth of $1, one year, split-adjusted
| Metric | ADMA | RXRX |
|---|---|---|
| Price | $9.96 | $4.03 |
| Market cap | $2.23B | $2.16B |
| Today | −1.58% | +8.92% |
| 1 month | +6.6% | +20.7% |
| 6 months | +8.9% | +41.9% |
| Year to date | −45.4% | −1.5% |
| 1 year | −36.2% | −14.6% |
| Revenue growth (YoY) | +2.0% | −60.1% |
| Gross margin | 69.4% | −49.8% |
| Net margin | 30.4% | −1708.0% |
| P/E (TTM) | 13.2× | — |
| Price / sales | 4.4× | 39.4× |
| Net cash | -$60.6M | $531.5M |
| Dividend yield | — | — |
| Volatility (60d) | 40.6% | 74.2% |
| Short % of float | 11.3% | 41.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).